Artemis FAQs

Yes, a PSA blood test is still an important screening tool for prostate cancer detection. While the Artemis/ProFuse platform improves the accuracy and precision of biopsies, the PSA test remains valuable for initial screening. It is recommended to consult with Dr Chabert who can assess the need for both PSA testing and targeted biopsies using the Artemis platform based on individual circumstances.

The Artemis/ProFuse platform offers several benefits for prostate cancer diagnosis and treatment. It provides accurate and selective prostatic biopsies, reducing the number of biopsies required and minimizing the side effects of the investigation. For men with suspicious lesions (Pirad 4 or 5), the platform allows for fewer biopsies while maintaining high detection accuracy. Furthermore, the platform's ability to record the exact placement of positive samples enables urologists to perform additional biopsies in the same spot over time, aiding in monitoring cancer characteristics and facilitating active surveillance.

Traditional prostate biopsies have been performed using transrectal ultrasound-guided needle placement, which carries a risk of infection and may make accessing anteriorly placed lesions difficult. In contrast, the Artemis platform utilizes a transperineal approach, avoiding needle placement through the bowel wall and allowing better access to the front part or anterior aspect of the prostate. Additionally, the Artemis platform provides a more accurate and reliable fusion of MRI and ultrasound images, reducing guesswork and improving the precision of targeted prostatic biopsies.

The Artemis/ProFuse platform is a system that combines 3D semi-robotic tracking and deformable MR-Ultrasound fusion to improve the accuracy and reliability of prostate cancer detection and diagnosis. It uses a mechanical robotic arm to stabilize and hold the ultrasound probe, eliminating prostate deformation during the biopsy procedure and enabling accurate and reproducible biopsy targeting. By overlaying previously obtained MRI images with real-time ultrasound images, the platform allows urologists like Dr Chabert to map out prostate lesions in a three-dimensional fashion, facilitating precise biopsy targeting.